REC Ref No.	IRAS No.	Name of Trial	Target Number of Participants Available?	Recruitment Target	Target Date To Recruit Participants Available?	Date Agreed To Recruit Target Number of Participants	Total Number of Participants Recruited at The Agreed Target Date	Date Study Closed to Recruitment	Recruitment Total	RTT Met?	Recruitment Closure Reason
20/WM/0123	282099	A randomized, double-blind, placebo-controlled, multi-centre study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia	Number Agreed	3	Date Agreed	29/01/2021	12	28/05/2020	12	Yes	Recruitment Finished
20/NE/0105	282026	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment	Number Agreed	4	Date Agreed	04/06/2020	3	29/05/2020	4	Yes	Recruitment Finished
20/NE/0104	282007	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants with Severe COVID-19	Number Agreed	6	Date Agreed	07/04/2020	6	29/05/2020	6	Yes	Recruitment Finished
19/LO/1566	267041	A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease	Number Agreed	1	Date Agreed	30/09/2020	0	06/04/2020	0	No	Recruitment Finished
19/ES/0095	268796	A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly	Number Agreed	20	Date Agreed	30/11/2019	0	17/11/2019	0	No	Withdrawn By Sponsor
19/EE/0164	261589	T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma.	Number Agreed	3	Date Agreed	07/09/2020	0	12/05/2020	0	No	Withdrawn By Sponsor
19/EE/0201	264655	A Randomised, Single-blind, Placebo-controlled, Phase 1b Single Ascending (Part A) and Multiple Dose (Part B) First-in-Man Study in Adult Patients with Non-transfusion-Dependent Beta-Thalassaemia or Low Risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN124	Number Agreed	3	Date Agreed	03/05/2021	0	20/03/2020	0	No	Withdrawn By Sponsor
18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Number Agreed	2	Date Agreed	30/06/2020	1	30/06/2020	1	No	Recruitment Finished
17/LO/1921	236323	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION	Number Agreed	1	Date Agreed	31/03/2020	1	31/03/2020	2	Yes	Recruitment Finished
18/EE/0099	239606	An open label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)	Number Agreed	4	Date Agreed	31/03/2020	2	31/03/2020	2	No	Recruitment Finished

19/SC/0031	257722	A randomised, placebo-controlled, double-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age	Number Agreed	2	Date Agreed	30/05/2021	0	05/08/2019	0	No	Recruitment Finished
18/WA/0385	254760	A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6- Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment	Number Agreed	5	Date Agreed	30/09/2019	0	31/07/2019	0	No	Recruitment Finished
18/LO/2023	253130	A double-blind, randomised, placebo controlled, adaptive design study of the efficacy, safety and pharmacokinetics of NT-814 in female subjects with moderate to severe vasomotor symptoms associated with the menopause	Number Agreed	5	Date Agreed	27/12/2019	4	06/08/2019	4	No	Recruitment Finished
19/LO/0660	253405	A Phase 2b/3 study to evaluate the safety, tolerability, and effects of Livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome	Number Agreed	2	Date Agreed	22/11/2019	3	22/11/2019	3	Yes	Recruitment Finished
18/EM/0311	254008	A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Disease (COPD)	Number Agreed	20	Date Agreed	01/08/2019	18	01/08/2019	18	No	Recruitment Finished
18/LO/1558	248946	A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)	Number Agreed	2	Date Agreed	29/02/2020	0	29/02/2020	0	No	Recruitment Finished
18/YH/0136	214921	A Multi-Centre, Pilot, Prospective, Clinical Investigation of DermaRepâ„¢ Device in the treatment of Venous Leg Ulcers.	Number Agreed	5	Date Agreed	30/09/2019	5	30/09/2019	5	Yes	Recruitment Finished
18/SW/0219	250410	A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AG-348 IN ADULT SUBJECTS WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA-AG348-C-010	Number Agreed	1	Date Agreed	31/01/2020	1	10/03/2020	1	Yes	Recruitment Finished
16/LO/1567	242092	A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody BGB-A317 versus Chemotherapy as Second Line Treatment in Patients with Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma	Number Agreed	2	Date Agreed	31/08/2020	5	09/04/2020	7	Yes	Recruitment Finished
17/LO/0182	213821	A Prospective, Randomized, Multicenter Controlled Trial of CERAMENTâ„¢|G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures	Number Agreed	5	Date Agreed	31/03/2020	4	31/03/2020	4	No	Recruitment Finished
17/LO/1018	224051	An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies	Number Agreed	2	Date Agreed	30/11/2019	2	30/11/2019	5	Yes	Recruitment Finished

18/ES/0071	241904	A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide	Number Agreed	5	Date Agreed	29/10/2020	1	24/03/2020	1	No	Withdrawn By Sponsor
18/NE/0214	245998	MN39158 - A Long Term Extension Study in Multiple Sclerosis	Number Agreed	1	Date Agreed	01/06/2020	3	01/06/2020	3	Yes	Recruitment Finished
18/NI/0129	218623	Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus LumiganÂ® 0.01% in ocular hypertensive or glaucomatous patients.	Number Agreed	4	Date Agreed	01/05/2020	1	01/05/2020	1	No	Recruitment Finished
18/LO/1007	242697	Patient-Reported Outcomes with the Accu-ChekÃ‚Â® Solo Micropump System vs. Multiple Daily Injection Therapy vs. mylife OmniPodÃ‚Â® in Patients with Type 1 Diabetes	Number Agreed	4	Date Agreed	31/05/2020	0	15/05/2020	0	No	Recruitment Finished
17/EM/0406	235483	A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia (PRTX-100-202)	Number Agreed	1	Date Agreed	30/07/2019	0	30/07/2019	0	No	Withdrawn By Sponsor
18/LO/1187	240011	(A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy)	Number Agreed	6	Date Agreed	23/09/2023	4	30/01/2020	4	No	Recruitment Finished
18/YH/0099	241430	A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimerâ€™s Disease (AD)	Number Agreed	5	Date Agreed	31/12/2019	4	26/03/2020	293	Yes	Withdrawn By Sponsor
18/LO/1461	245412	A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)	Number Agreed	2	Date Agreed	30/09/2019	1	30/09/2019	1	No	Recruitment Finished
18/LO/0719	235423	A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)	Number Agreed	5	Date Agreed	30/04/2019	0	01/07/2019	1	No	Recruitment Finished
18/LO/0995	244737	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physicianâ€™s Choice in Participants with Advanced Endometrial Cancer	Number Agreed	4	Date Agreed	18/12/2019	6	18/12/2019	7	Yes	Recruitment Finished
18/NW/0109	234734	PHIL evaluation in the endovascular treatment of intracranial dural AVF	Number Agreed	4	Date Agreed	31/12/2019	2	31/12/2019	2	No	Recruitment Finished
18/LO/0235	240315	An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials	Number Agreed	1	Date Agreed	01/03/2020	3	01/03/2020	3	Yes	Recruitment Finished
18/NW/0107	236834	PHIL evaluation in the endovascular treatment of intracranial cerebral ArterioVenous Malformation	Number Agreed	6	Date Agreed	31/08/2019	0	31/08/2019	0	No	Withdrawn By Sponsor
18/EM/0153	240773	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency	Number Agreed	1	Date Agreed	17/09/2020	2	28/02/2020	2	Yes	Recruitment Finished

18/LO/0070	238482	A Pivotal Clinical Trial of the Management of th Medically-Refractory Dyskinesis Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinsonâ€™s Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System	Number Agreed	6	Date Agreed	02/03/2020	0	27/02/2020	0	No	Recruitment Finished
17/SC/0639	236312	A Phase 3 Open-Label, single-Arm Study to Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Haemophila A Patients with Residual FVIII Levels 1 IU/dL Receiving Prophylactic FVIII Infusions	Number Agreed	1	Date Agreed	30/09/2019	0	30/09/2019	0	No	Recruitment Finished
17/EE/0474	229785	The open-label, randomised, multi-centre, parallel group, two-arm study to assess the safety, overall tolerability, and antiviral activity of Brincidofovir versus standard of care for treatment of adenovirus infections in high-risk paediatric allogeneic haematopoietic cell transplant recipients	Number Agreed	5	Date Agreed	21/02/2020	1	21/02/2020	1	No	Recruitment Finished
18/WM/0006	225197	An Adaptive, Sequential Evaluation of Powered and Manual Circular Staplers in Left-Sided Colorectal Anastomoses	Number Agreed	3	Date Agreed	31/12/2019	3	31/12/2019	3	Yes	Recruitment Finished
17/NE/0300	225917	A phase II, randomised, double-blind, placebo-controlled, parallel-group, multicentre study investigating the efficacy and safety of Sepranolone (UC1010) in patients with PMDD	Number Agreed	18	Date Agreed	31/03/2020	17	20/08/2019	17	No	Recruitment Finished
17/LO/1695	234684	A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Medicated Gene Transfer of Human Factor VIII in Haemphilia A Patients with Residual FVIII Levels 1 IU/dl Receiving Prophylactic FVIII Infusions.	Number Agreed	1	Date Agreed	04/10/2019	3	04/10/2019	3	Yes	Recruitment Finished
17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac Resynchronization Therapy	Number Agreed	8	Date Agreed	31/10/2019	6	31/10/2019	6	No	Recruitment Finished
17/EM/0338	229242	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Number Agreed	1	Date Agreed	22/11/2018	6	08/10/2019	6	Yes	Recruitment Finished
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimerâ€™s disease	Number Agreed	10	Date Agreed	31/10/2019	4	31/10/2019	3,786	Yes	Recruitment Finished
17/LO/1590	229278	A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585).	Number Agreed	4	Date Agreed	01/10/2019	4	01/10/2019	4	Yes	Recruitment Finished
17/EE/0177	220722	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).	Number Agreed	3	Date Agreed	01/06/2020	7	01/06/2020	7	Yes	Recruitment Finished

17/EM/0154	222912	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinsonâ€™s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)	Number Agreed	4	Date Agreed	30/09/2019	4	30/09/2019	4	Yes	Recruitment Finished
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimerâ€™s Disease	Number Agreed	4	Date Agreed	30/06/2020	4	30/06/2020	4	Yes	Recruitment Finished
17/LO/0525	221541	A prospective, double-masked, randomized, multicenter, active- controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORTÃ‚Â® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3).	Number Agreed	1	Date Agreed	01/09/2019	1	01/09/2019	1	Yes	Recruitment Finished
16/SW/0120	201715	Study of the optimum duration of acoustic pulse thrombolysis procedure in the treatment of acute submassive pulmonary embolism	Number Agreed	8	Date Agreed	19/03/2020		19/03/2020	0	No	Withdrawn By Sponsor
17/ES/0051	223060	CANC 33870: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer	Number Agreed	3	Date Agreed	30/09/2019	6	31/12/2019	6	Yes	Withdrawn By Sponsor
17/NW/0254	225698	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy	Number Agreed	6	Date Agreed	15/10/2018	12	31/12/2019	12	Yes	Recruitment Finished
17/WM/0425	232819	A phase III trial evaluating the efficacy and safety of the SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents with HDM allergic asthma	Number Agreed	4	Date Agreed	21/05/2020	2	18/09/2019	2	No	Withdrawn By Host
16/NW/0877	216860	A Safety and Tolerability Study of LY3303560 in Alzheimer's Disease	Number Agreed	8	Date Agreed	31/01/2020	1	31/01/2020	1	No	Recruitment Finished
17/EM/0241	223736	Safety and efficacy analysis of FRED/FRED Jr embolic device in aneurysm treatment	Number Agreed	10	Date Agreed	31/12/2019	21	31/12/2019	21	Yes	Recruitment Finished
17/WS/0120	225090	A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patientâ€™s self-reported symptoms and their impacts	Number Agreed	2	Date Agreed	01/09/2019	8	01/09/2019	8	Yes	Recruitment Finished
17/NW/0180	220257	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who	Number Agreed	2	Date Agreed	15/02/2020	1	15/02/2020	1	No	Recruitment Finished
16/EM/0465	214926	A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations	Number Agreed	1	Date Agreed	30/09/2019	0	30/09/2019	2	Yes	Recruitment Finished

17/EE/0081	219405	An open label, single arm pilot study of OncoSilâ„¢, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.	Number Agreed	2	Date Agreed	01/06/2020		01/06/2020	6	Yes	Recruitment Finished
17/EE/0080	220727	A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen	Number Agreed	5	Date Agreed	31/10/2019	4	31/10/2019	4	No	Recruitment Finished
17/LO/0103	216784	A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache	Number Agreed	2	Date Agreed	19/12/2019	0	19/12/2019	0	No	Recruitment Finished
16/SC/0630	209259	Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohnâ€™s Disease	Number Agreed	2	Date Agreed	11/10/2019	0	11/10/2019	0	No	Recruitment Finished
17/EE/0330	213102	A Prospective, Non-randomized, Consecutive Series, Multicentre, Observational Study to Evaluate the Clinical Outcome of Ceramic-on-Ceramic Hip Resurfacing Arthroplasty Using the H1 hip joint ceramic non-porous non-cemented prosthesis	Number Agreed	50	Date Agreed	30/09/2019	38	30/09/2019	40	No	Recruitment Finished
17/LO/0082	217324	A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery	Number Agreed	3	Date Agreed	30/09/2019	10	30/09/2019	10	Yes	Recruitment Finished
17/EM/0005	215706	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction	Number Agreed	8	Date Agreed	05/01/2020		05/01/2020	0	No	Withdrawn By Sponsor
17/SC/0411	217829	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100X (DNA PLASMID VECTORS EXPRESSING HPV-16 E6/E7, HPV-18 E6/E7) DELIVERED intramuscularly FOLLOWED BY EP WITH CELLECTRAÂ® 5PSP FOR THE TREATMENT OF HISTOLOGICALLY PROVEN CIN2 OR CIN3 ASSOCIATED WITH HPV-16 AND/OR HPV-18	Number Agreed	1	Date Agreed	22/09/2020	2	02/07/2019	2	Yes	Recruitment Finished
16/LO/0675	147355	A PHASE 2, INTERNATIONAL, MULTICENTER, RANDOMIZED, OPENLABEL, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) ALONE AND IN COM+H768BINATION WITH DURVALUMAB (MEDI4736) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTION OR DECITABINE	Number Agreed	3	Date Agreed	31/10/2019	0	31/10/2019	0	No	Withdrawn By Sponsor
15/NE/0406	186547	MNA-3521-011 - A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH)	Number Agreed	5	Date Agreed	31/12/2019	1	31/12/2019	1	No	Recruitment Finished

15/LO/1680	185421	Post Market Clinical Follow-Up Evaluation of BioPoly RS Partial Resurfacing Patella Implant	Number Agreed	5	Date Agreed	01/10/2019	0	01/10/2019	0	No	Recruitment Finished
16/LO/0124	182955	A study of the ReCor Paradise System in Clinical Hypertension	Number Agreed	10	Date Agreed	17/12/2019	11	17/12/2019	11	Yes	Recruitment Finished
15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Number Agreed	6	Date Agreed	25/11/2019	2	25/11/2019	2	No	Recruitment Finished
15/LO/1641	180563	Global Clinical Study of Renal Denervation with the Symplicity Spyralâ„¢ multielectrode renal denervation system in Patients with Uncontrolled Hypertension in the Absence of Antihypertensive Medications	Number Agreed	5	Date Agreed	01/11/2019	16	01/11/2019	16	Yes	Withdrawn By Host
15/LO/1640	180561	Global Clinical Study of Renal Denervation with the Symplicity Spyralâ„¢ multielectrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy	Number Agreed	1	Date Agreed	31/12/2019	5	31/12/2019	5	Yes	Recruitment Finished
15/LO/1192	183464	A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses.	Number Agreed	4	Date Agreed	31/10/2019	4	31/10/2019	4	Yes	Recruitment Finished
14/LO/0521	146148	A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.	Number Agreed	1	Date Agreed	01/12/2019	2	01/12/2019	2	Yes	Recruitment Finished